Literature DB >> 25644329

Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Karisma Patel1, Ashley S Crumby, Holly D Maples.   

Abstract

Sixty years later, the question that still remains is how to appropriately utilize vancomycin in the pediatric population. The Infectious Diseases Society of America published guidelines in 2011 that provide guidance for dosing and monitoring of vancomycin in adults and pediatrics. However, goal vancomycin trough concentrations of 15-20 μg/mL for invasive infections caused by methicillin-resistant Staphylococcus aureus were based primarily on adult pharmacokinetic and pharmacodynamic data that achieved an area under the curve to minimum inhibitory concentration ratio (AUC/MIC) of ≥400. Recent pediatric literature shows that vancomycin trough concentrations needed to achieve the target AUC/MIC are different than the adult goal troughs cited in the guidelines. This paper addresses several thoughts, including the role of vancomycin AUC/MIC in dosing strategies and safety monitoring, consistency in laboratory reporting, and future directions for calculating AUC/MIC in pediatrics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25644329     DOI: 10.1007/s40272-015-0117-5

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  42 in total

Review 1.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

2.  In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.

Authors:  Faruk Oktem; Meltem Koyuncu Arslan; Fehmi Ozguner; Ozden Candir; H Ramazan Yilmaz; Metin Ciris; Efkan Uz
Journal:  Toxicology       Date:  2005-08-19       Impact factor: 4.221

3.  Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.

Authors:  Lindsey Pritchard; Catherine Baker; James Leggett; Paul Sehdev; Allen Brown; K Bruce Bayley
Journal:  Am J Med       Date:  2010-12       Impact factor: 4.965

4.  Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.

Authors:  Adam Frymoyer; B Joseph Guglielmo; Stephen D Wilson; Sarah B Scarpace; Leslie Z Benet; Adam L Hersh
Journal:  Pharmacotherapy       Date:  2011-09       Impact factor: 4.705

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

7.  Vancomycin: we can't get there from here.

Authors:  Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

8.  Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients.

Authors:  Brady S Moffett; Pamela S Hilvers; Kimberly Dinh; Ayse A Arikan; Paul Checchia; Ronald Bronicki
Journal:  Congenit Heart Dis       Date:  2014-06-17       Impact factor: 2.007

9.  Improved vancomycin dosing in children using area under the curve exposure.

Authors:  Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

10.  Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children.

Authors:  Ahmed R Ragab; Maha K Al-Mazroua; Mona A Al-Harony
Journal:  Infect Dis Ther       Date:  2013-03-26
View more
  8 in total

Review 1.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

2.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

3.  Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit.

Authors:  Bo Zhou; Wenyi Xiong; Ke Bai; Hongxing Dang; Jing Li; Feng Xu; Yue-Qiang Fu; Chengjun Liu
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

4.  AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants.

Authors:  Abdullah Alsultan; Manal Abouelkheir; Ahmad Albassam; Emad Alharbi; Ahmed Assiri; Saeed Alqahtani
Journal:  Indian J Pediatr       Date:  2020-01-27       Impact factor: 1.967

5.  Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Ree Nar Yoo; Seo Hee Kim; Jina Lee
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

Review 6.  Expanding Existing Antimicrobial Stewardship Programs in Pediatrics: What Comes Next.

Authors:  Matthew P Kronman; Ritu Banerjee; Jennifer Duchon; Jeffrey S Gerber; Michael D Green; Adam L Hersh; David Hyun; Holly Maples; Colleen B Nash; Sarah Parker; Sameer J Patel; Lisa Saiman; Pranita D Tamma; Jason G Newland
Journal:  J Pediatric Infect Dis Soc       Date:  2018-08-17       Impact factor: 3.164

7.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06

8.  Does vancomycin administered at an empirical dose ensure coverage of pediatric patients against gram-positive pathogens?

Authors:  Frederico Ribeiro Pires; Stefano Ivani de Paula; Artur Figueiredo Delgado; Werther Brunow de Carvalho; Nilo José Coelho Duarte; Ronaldo Morales Júnior; Silvia Regina Cavani Jorge Santos
Journal:  Rev Bras Ter Intensiva       Date:  2020 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.